The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo
暂无分享,去创建一个
Elizabeth Garrett-Mayer | Ping Lu | L. Garraway | G. Hortobagyi | P. Lu | A. Sood | R. Langley | K. Dalby | T. Gonda | E. Garrett-Mayer | Charles D Smith | N. McMillan | Heather Tye | R. Drake | E. Jones | W. Elmquist | G. Armaiz-Pena | W. Merritt | S. Pradeep | H. Dalton | J. Kraveka | Yvonne G Lin | Heather Venant | Mehrdad Rahmaniyan | E. Ellen Jones | Michael B. Lilly | Richard R. Drake | Jacqueline M. Kraveka | Charles D. Smith | Christina Voelkel-Johnson | J. Hansen | R. Previs | S. Zahn | C. Voelkel-Johnson | Angie M. Torres-Adorno | Z. Oo | A. Stevenson | M. K. Pitner | Monica E. Reyes | M. Lilly | Mehrdad Rahmaniyan | F. Bokhari | E. Haaksma | Matthias Treu | Heather Venant | Ashley Davis | R. L. Coleman | Daniel T. W. Clarke | Max V. Ranall | Melanie Murrell
[1] Charles D Smith,et al. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts , 2011, Cancer biology & therapy.
[2] A. Bielawska,et al. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. , 2013, The Journal of clinical investigation.
[3] Jayne M. Silver,et al. Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model , 2015, Molecular Cancer Therapeutics.
[4] S. Pyne,et al. The sphingosine kinase inhibitor 2‐(p‐hyroxyanilino)‐4‐(p‐chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress‐dependent mechanism , 2013, British journal of pharmacology.
[5] L. Obeid,et al. Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors. , 2013, Biochimica et biophysica acta.
[6] W. J. Dyer,et al. A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.
[7] X. Rao,et al. Gamma‐tocotrienol induces apoptosis and autophagy in prostate cancer cells by increasing intracellular dihydrosphingosine and dihydroceramide , 2012, International journal of cancer.
[8] S. Rauser,et al. Normalization in MALDI-TOF imaging datasets of proteins: practical considerations , 2011, Analytical and bioanalytical chemistry.
[9] Jin H. Song,et al. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. , 2014, Blood.
[10] A. Bielawska,et al. Sphingolipid analysis by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). , 2010, Advances in experimental medicine and biology.
[11] A. Kopp-Schneider,et al. A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy , 2014, Cell Death and Disease.
[12] J. Aragon-Ching,et al. Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies , 2014, Therapeutics and clinical risk management.
[13] Y. Zhuang,et al. Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn’s disease , 2010, Inflammopharmacology.
[14] B. Foster,et al. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. , 1997, Cancer research.
[15] Michael D. Henry,et al. Assessing Tumor Growth and Distribution in a Model of Prostate Cancer Metastasis using Bioluminescence Imaging , 2006, Clinical & Experimental Metastasis.
[16] Y. Hannun,et al. Identification of Dihydroceramide Desaturase as a Direct in Vitro Target for Fenretinide* , 2011, The Journal of Biological Chemistry.
[17] J. Casas,et al. Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II[S] , 2014, Journal of Lipid Research.
[18] T. Tirodkar,et al. Sphingolipids in apoptosis. , 2012, Experimental oncology.
[19] L. Del Valle,et al. Targeting Sphingosine Kinase Induces Apoptosis and Tumor Regression for KSHV-Associated Primary Effusion Lymphoma , 2013, Molecular Cancer Therapeutics.
[20] C. Wallington-Beddoe,et al. Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression. , 2014, Cancer research.
[21] D. Beach,et al. Myc confers androgen-independent prostate cancer cell growth. , 2003, The Journal of clinical investigation.
[22] C. Xie,et al. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer , 2015, Cancer biology & therapy.
[23] J. Stebbing,et al. Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer , 2011, Nature Reviews Urology.
[24] Y. Peterson,et al. Characterization of Isoenzyme-Selective Inhibitors of Human Sphingosine Kinases , 2012, PloS one.
[25] S. Pitson,et al. Roles, regulation and inhibitors of sphingosine kinase 2 , 2013, The FEBS journal.
[26] P. Lu,et al. In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL , 2006, Cancer Gene Therapy.
[27] T. Mosher,et al. Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase , 2011, Inflammopharmacology.
[28] Daniel Bottomly,et al. Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation , 2013, PloS one.
[29] D. Tindall,et al. Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells* , 2006, Journal of Biological Chemistry.
[30] Deepak Poudyal,et al. Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. , 2010, Carcinogenesis.
[31] L. Chan,et al. Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640. , 2013, Anticancer research.
[32] L. Obeid,et al. Regulation of the sphingosine kinase/sphingosine 1-phosphate pathway. , 2013, Handbook of experimental pharmacology.
[33] J. Nofer,et al. Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R−/−) mice , 2012, Thrombosis and Haemostasis.
[34] A. Bielawska,et al. Involvement of Dihydroceramide Desaturase in Cell Cycle Progression in Human Neuroblastoma Cells* , 2007, Journal of Biological Chemistry.
[35] L. Rhodes,et al. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. , 2010, Endocrinology.
[36] M. Burow,et al. Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival , 2014, Pharmacological reports : PR.
[37] Charles D Smith,et al. Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion. , 2012, Journal of hepatology.
[38] Charles D Smith,et al. A Novel Sphingosine Kinase Inhibitor Induces Autophagy in Tumor Cells , 2010, Journal of Pharmacology and Experimental Therapeutics.
[39] M. Burow,et al. Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer , 2012, Experimental biology and medicine.
[40] Steven Elliott,et al. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2 , 2011, Cancer biology & therapy.
[41] Benjamin A. Neely,et al. MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma , 2014, Proteomics.
[42] T. Visakorpi,et al. Genetic alterations in hormone-refractory recurrent prostate carcinomas. , 1998, The American journal of pathology.
[43] Charles D Smith,et al. Inhibition of Sphingosine Kinase-2 Suppresses Inflammation and Attenuates Graft Injury after Liver Transplantation in Rats , 2012, PloS one.
[44] Y. Zhuang,et al. Pharmacology and Antitumor Activity of ABC294640, a Selective Inhibitor of Sphingosine Kinase-2 , 2010, Journal of Pharmacology and Experimental Therapeutics.
[45] Y. Zhuang,et al. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib , 2011, Investigational New Drugs.